Product news from the 01/16/07 news brief

Share this article:
Victory Pharma has inked a deal with Hi-Tech Pharmacal for exclusive US commercial license rights to its Naprelan (naproxen sodium) formulation for the treatment of rheumatoid arthritis. The product will be marketed through Victory’s physician-based field sales force deployed throughout the US with plans for sales force expansion under way. Victory’s promotion of Naprelan is expected to begin during the first quarter of 2007. Acorda Therapeutics said it has completed the expansion of its sales force to 65 people, 52 of whom are area business managers calling on specialists and primary care physicians. The Acorda sales team promotes Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For 2005, Acorda reported shipments of Zanaflex to wholesalers at $18.6 million, using its pilot sales force of 14 professionals. In March 2006, the company expanded its sales force to 32. Shipments to wholesalers increased to $31 million. Galderma Laboratories announced the availability of a new MetroGel (metronidazole) Topical Gel kit for the topical treatment of the inflammatory lesions of rosacea.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.